WRTL Responds to FDA v. the Alliance for Hippocratic Medicine

Today, the Supreme Court of the United States heard arguments for the case FDA v. the Alliance for Hippocratic Medicine. In recent years, the FDA has removed the safeguards surrounding the chemical abortion drug mifepristone, including decisions in 2016 and 2021 to loosen regulations. These include removing the in-person dispensing requirement, increasing the gestational age from 7 to 10 weeks, not requiring the reporting of non-fatal adverse events in patients, and removing the requirement for a 14-day in-person follow-up.  

Heather Weininger, Wisconsin Right to Life’s executive director, responded, “Every chemical abortion not only takes the life of a preborn child but puts women and girls in grave danger. This is a matter of women’s health and advocating for true informed consent and protections for women and their preborn children. If we truly care about women’s health and as the abortion industry claims that abortion is part of reproductive health care, then we should begin by at the least ensuring a physician sees women before having a chemical abortion. How can anyone claim health care is happening without even clearly identifying the stage of pregnancy a woman is in?”  

Gracie Skogman, Wisconsin Right to Life’s legislative director responded, “Women deserve better than the lies and coercion of the abortion industry. We call on the Supreme Court to defend women and girls and ensure the FDA is held to account for their failure to do so.” 

Chemical abortions now represent 63% of all abortions in the United States and not only take the lives of preborn children but put women and girls at far greater risk for complications. In the years since the chemical abortion pill was first approved in the 1990s, the rate of abortion pill-related ER visits has increased by more than 500% and has four times the complication rate of surgical abortion. 

*****   

Media Contact:
Gracie Skogman, Legislative Director
gskogman@wrtl.org
(414) 308-1054